



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)
from Capital District Health Authority/Cancer Care Nova Scotia**

**Guidelines for the Role of Recombinant Humanized Thyroid Stimulating Hormone
(rhTSH) in the Treatment of Thyroid Cancer**

Approved Use:

Recombinant Humanized Thyroid Stimulating Hormone (rhTSH): As a **single** agent may be used for preparation of radioiodine remnant ablation in patients with papillary or follicular thyroid cancer who have undergone thyroidectomy as **treatment** for thyroid cancer. RhTSH would be a reasonable alternate to thyroid hormone withdrawal in patients who are unable to tolerate the prolonged hypothyroidism state or who cannot achieve satisfactory elevation of endogenous TSH. In any one patient, this may include the following situations:

RhTSH may be used in any **new** patients (with papillary or follicular histology) in preparation for radioiodine remnant ablation.

A small proportion (10%) of these new patients may need the treatment **multiple** times. RhTSH may be used in patients with **previously incomplete remnant ablation** or a **recurrence** (10 %) of thyroid cancer and require therapeutic radioiodine ablation.

- This policy recommendation represents an **extension** of the current restriction of rhTSH (ongoing monitoring) and a restriction to the treatment of patients with papillary or follicular thyroid cancer.